title: Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.
abstract: OBJECTIVE
  Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS®) tablet disintegrated in water (MUPS® formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems.
  
  
  METHODS
  Nonblinded, two-phase cross-over trial.
  
  
  RESULTS
  In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS® formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS® over suspension) was 0.5 (0.06-2.37).
  
  
  CONCLUSIONS
  In this population, omeprazole MUPS® formulation has no apparent advantage over the more easily administered suspension formulation.
authors.affiliation: Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Gent, Belgium. koen.boussery@ugent.be
authors.forename: Koen
authors.initials: K
authors.lastname: Boussery
authors.forename: Julie
authors.initials: J
authors.lastname: De Smet
authors.forename: Pieter
authors.initials: P
authors.lastname: De Cock
authors.forename: Saskia
authors.initials: S
authors.lastname: Vande Velde
authors.forename: Els
authors.initials: E
authors.lastname: Mehuys
authors.forename: Peter
authors.initials: P
authors.lastname: De Paepe
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Remon
authors.forename: Jan F P
authors.initials: JF
authors.lastname: Van Bocxlaer
authors.forename: Myriam
authors.initials: M
authors.lastname: Van Winckel
mesh_terms: D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D002648:Child; D018592:Cross-Over Studies; D002658:Developmental Disabilities / Q000150:complications* / Q000503:physiopathology; D004750:Enteral Nutrition; D005260:Female; D005774:Gastrostomy; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012720:Severity of Illness Index; D017693:Sodium Bicarbonate / Q000737:chemistry; D013535:Suspensions; D014867:Water / Q000737:chemistry; D055815:Young Adult
chemical_list: D000897:Anti-Ulcer Agents; D013535:Suspensions; D014867:Water; D017693:Sodium Bicarbonate; D009853:Omeprazole